TITLE: A clinical and virological study of hepatitis C virus-related cryoglobulinemia in Germany
Abstract:
Background/Aims: Several reports, especially from Southern Europe, have demonstrated a close association between hepatitis C virus (HCV) infection and mixed cryoglobulinemia. In this study we have analyzed the significance of HCV-related cryoglobulinemia in Germany.
Methods: Sera from 79 patients with cryoglobulinemia of type I (n=21), II (n=28) or III (n=30) were investigated for HCV markers. Furthermore, 132 consecutive patients with chronic hepatitis C were studied for the presence of cryoglobulins. Genotypes of HCV were determined according to Simmonds, and HCV-RNA concentrations were measured in patients with and without cryoglobulinemia.
Results: In 79 patients with cryoglobulinemia we found anti-HCV antibodies in 17 (22%) and HCV-RNA in 11 patients (14%), HCV antibodies were more frequent in essential (44%) compared to secondary mixed cryoglobulinemia (15%), In 132 patients with chronic HCV infection cryoglobulins were detected in 37 patients (28%), in 21 of them at low levels. Clinical symptoms due to cryoglobulinemia were observed in eight of the 37 patients, severe vasculitis in three patients with high cryocrit-levels and cryoprecipitation at room temperature. HCV genotype 1 and subtype Ib were most prevalent, both in patients with and without cryoglobulinemia, and mean HCV-RNA levels were not different between the two groups. Comparison of HCV-RNA levels in cryoprecipitates, supernatant and native serum suggests binding of HCV-RNA to the cryoprecipitate with different affinity in individual patients.
Conclusions: The lower prevalence of HCV-related cryoglobulinemia in our study compared with data from Italy and France suggests a south-north gradient in the prevalence of HCV-associated cryoglobulinemia in Europe.
AUTHOR: Weiner SM, Berg T, Berthold H, Weber S, Peters T, Blum HE, Hopf U, Peter HH; SOURCE: JOURNAL OF HEPATOLOGY 29: (3) 375-384 SEP 1998
Hep C and Fatty Liver Disease Linked
Pittsburgh researchers have found an enzyme known to participate in fat production is elevated in those with Hepatitis C. Further exploration of this enzyme could help physicians better predict which HCV patients are at risk of developing fatty liver disease....
Anadys' ANA773 Hepatitis C Phase I Trials in Netherlands
Reducing the dosing schedule in half, Anadys Pharmaceuticals continues its investigation of ANA773, a Toll-Like Receptor-7 agonist prodrug. Approaching the Hepatitis C virus differently from most other contenders, Phase I clinical trials evaluating the safety, tolerability and viral-load decline associated...